|Table of Contents|

Research advances in UBE2C and its current status with colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 04
Page:
677-680
Research Field:
Publishing date:

Info

Title:
Research advances in UBE2C and its current status with colorectal cancer
Author(s):
Wei Zhen1; Chang Wanmei1; Guo Xiaoyu1; Wang Qian2; Zhang Huiqing2
1.Chengde Medical College，Hebei Chengde 067000,China;2.Baoding First Central Hospital,Hebei Baoding 071000,China.
Keywords:
UBE2C; ubiquitin proteasome system; colorectal cancer
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2019.04.035
Abstract:
In the world,the incidence of colorectal cancer (CRC) is third in the malignant tumor,and the mortality rate is fourth.In recent years,with the improvement of people's living standards and changes in lifestyle and dietary structure,the incidence of CRC and mortality have been on the rise.The ubiquitin proteasome system (UPS) is an ATP-dependent protein degradation pathway in the cytoplasm and nucleus.It regulates its degraded proteins through ubiquitination-proteasome-deubiquitination mechanisms to maintain homeostasis.When the regulated protein loses its stability,it causes cancer and other diseases.Ubiquitin conjugating enzyme (UBE2C),also known as ubiquitin binding enzyme 10 (UBH10),plays an important biological role in UPS,and is necessary for cell cycle progression and cyclin degradation.UBE2C is highly expressed in the tissues of patients with colorectal cancer and is associated with the proliferation,apoptosis,invasiveness,prognosis and chemosensitivity of tumor cells.It has been confirmed that UBE2C can be used as a potential tumor marker for colorectal cancer diagnosis,prognosis,lymph node metastasis and a new target for colorectal cancer gene therapy.This article reviews the progress of UBE2C in colorectal cancer in recent years.

References:

［1］Jemal A,Bray F,Center MM,et al.Global cancer statistics［J］.Ca A Cancer Journal for Clinicians,2015,65(2):87-108.
［2］Lan MG,Qing HT,Wang LS.Expressions of microRNA-101 and cyclooxygenase-2 in colorectal cancer［J］.The Journal of Practical Medicine,2016,32(5):739-742.［赖明广,青海涛,王立生.microRNA-101和COX-2在结肠癌中的表达及其临床意义［J］.实用医学杂志,2016,32(5):739-742.］
［3］Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.Ca A Cancer Journal for Clinicians,2016,66(2):115.
［4］Jiang CX,Shen YZ,Zhang ZH,et al.Analysis of incidence and survival rate of cancer among residents in Haining city from 2003 to 2015［J］.China Cancer,2018,27(4):267-272.［姜春晓,沈永洲,张志浩,等.2003-2015年浙江省海宁市居民癌症发病率及生存率分析［J］.中国肿瘤,2018,27(4):267-272.］
［5］Chen D,Dou QP.The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention［J］.Current Protein & Peptide Science,2010,11(6):459.
［6］Bennett EJ,Harper JW.DNA damage:Ubiquitin marks the spot［J］.Nature Structural & Molecular Biology,2008,15(1):20.
［7］Goldknopf IL,Busch H.Isopeptide linkage between nonhistone and histone 2A polypeptides of chromosomal conjugate-protein A24［J］.Proceedings of the National Academy of Sciences of the United States of America,1977,74(3):864-868.
［8］Nalepa G,Rolfe M,Harper JW.Drug discovery in the ubiquitin-proteasome system［J］.Nature Reviews Drug Discovery,2006,5(7):596.
［9］Wang SB,Wang F.Ubiquitin-conjugating enzyme E2C and tumors［J］.Journal of Medical Postgraduates,2015,28(5):543-548.［王少冰,王芳.泛素结合酶E2C与肿瘤的关系研究进展［J］.医学研究生学报,2015,28(5):543-548.］
［10］Han SS,Sun H,Liu QG.Research advances in UbcH10 and its relationship with cancer［J］.Chinese Journal of Clinical Oncology,2011,38(14):867-869.［韩少山,孙昊,刘青光.UbcH10与肿瘤关系研究进展［J］.中国肿瘤临床,2011,38(14):867-869.］
［11］Wang R,Song Y,Liu X,et al.UBE2C induces EMT through Wnt/β-catenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A［J］.International Journal of Oncology,2017,50(4):1116.
［12］Ree JHV,Jeganathan KB,Malureanu L,et al.Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation［J］.Journal of Cell Biology,2010,188(1):83.
［13］Chang L,Zhang Z,Yang J,et al.Molecular architecture and mechanism of the anaphase-promoting complex［J］.Nature,2014,513(7518):388-393.
［14］Summers MK,Pan B,Mukhyala K,et al.The unique n-terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC［J］.Molecular Cell,2008,31(4):544-556.
［15］Fujita T,Ikeda H,Taira N,et al.Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer［J］.Bmc Cancer,2009,9(1):87.
［16］Hanahan D,Weinberg RA.Hallmarks of cancer:The next generation［J］.Cell,2011,144(5):646.
［17］Okamoto Y,Ozaki T,Miyazaki K,et al. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme［J］.Cancer Research,2003,63(14):4167-4173.
［18］Hao Z,Zhang H,Cowell J.Ubiquitin-conjugating enzyme UBE2C:Molecular biology,role in tumorigenesis,and potential as a biomarker［J］.Tumor Biology,2012,33(3):723-730.
［19］Rui W,Yue S,Xi L,et al.UBE2C induces EMT through Wnt/β-catenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A［J］.International Journal of Oncology,2017,50(4):1116-1126.
［20］Chen S,Chen Y,Hu C,et al.Association of clinicopathological features with UbcH10 expression in colorectal cancer［J］.J Cancer Res Clin Oncol,2010,136(3):419-426.
［21］Chen SM,Chen YJ,Hu CJ.Lymph node metastasis of colorectal cancer and expression of UbcH10［J］.Laboratory Medicine & Clinic,2015,12(20):3035-3037.［陈世敏,陈英剑,胡成进.结直肠癌淋巴结转移与泛素结合酶UbcH10的表达［J］.检验医学与临床,2015,12(20):3035-3037.］
［22］Zhang Y,Tian S,Li X,et al.UBE2C promotes rectal carcinoma via miR-381［J］.Cancer Biology & Therapy,2018,19(3):230-238.
［23］Zhang HQ,Zhao G,Ke B,et al.Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients［J］.Eur Rev Med Pharmacol Sci,2018,22(6):1665-1671.
［24］Pellino G,Pallante P,Malapelle U,et al.UbcH10 overexpression is less pronounced in older colorectal cancer patients［J］.International Journal of Colorectal Disease,2016,31(7):1-2.
［25］Takahashi Y,Ishii Y,Nishida Y,et al.Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH［J］.Cancer Genetics & Cytogenetics,2006,168(1):30-35.
［26］Takayama T,Miyanishi K,Hayashi T,et al.Colorectal cancer:Genetics of development and metastasis［J］.Journal of Gastroenterology,2006,41(3):185-192.
［27］Shankaran V,Wisinski KB,Mulcahy MF.The role of molecular markers in predicting response to therapy in patients with colorectal cancer［J］.Molecular Diagnosis & Therapy,2008,12(2):87-98.
［28］Chen D,Dou QP.The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention［J］.Current Protein & Peptide Science,2010,11(6):459.
［29］Chen SS,Wang QD,Wu JY,et al.Inhibitory effect of UbcH10 gene silencing on colorectal cancer cell xenografts［J］.Chinese Journal of Public Health,2012,28(9):1197-1199.［陈世敏,王启栋,吴建英,等.UbcH10基因沉默对裸鼠移植性大肠癌抑制作用［J］.中国公共卫生,2012,28(9):1197-1199.］
［30］Bavi P,Uddin S,Ahmed M,et al.Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma［J］.American Journal of Pathology,2011,178(5):2109-2120.
［31］Li SZ,Song Y,Zhang HH,et al.UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer［J］.Sci Rep,2014,4(4):6910.
［32］Cacciola NA,Calabrese C,Malapelle U,et al.UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients［J］.Molecular Carcinogenesis,2016,55(5):793-807.

Memo

Memo:
河北省卫生计委科研基金（编号：20171069）
Last Update: 1900-01-01